Cognitive ImpairmentNCT07842679
Cognitive Impairment in Older Adults With Hematologic Malignancies
An observational study of Cognitive Impairment and Hematologic Malignancies, run by Assiut University.
Trial summary
This cross-sectional study aims to determine the prevalence of cognitive impairment and evaluate its relationship with activities of daily living among older adults with hematologic malignancies receiving chemotherapy. Read more about this study
- Who is it for?
- Ages 65 years and older
- Conditions the study is for
- Cognitive Impairment, Hematologic Malignancies, Chemotherapy Effect
- How many people
- 120 participants
- Where
- No sites listed yet
- Study dates
- 26 Sep 2026to 25 Feb 2028
- Phase
- Observational
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 65 years and older
- All sexes
- No healthy volunteers
- Older adult
Study population: Older adults aged 65 years or older with confirmed hematologic malignancies receiving chemotherapy at Assiut University Hospitals.
Who may be able to join
- - Age 65 years or older
- Confirmed diagnosis of hematologic malignancy
- Currently receiving chemotherapy
- Able to communicate and participate in cognitive assessment
- Written informed consent
Who cannot join
- - Previously diagnosed dementia before the diagnosis of malignancy
- Delirium at the time of assessment
- Severe visual or hearing impairment interfering with cognitive testing
- History of major neurological disorders affecting cognition
- Severe psychiatric illness affecting cognitive assessment
- Critically ill patients unable to complete study assessment
Trial locations and contacts
No sites are listed yet. Contact the study team or a site near you to ask about taking part.
About this study
Official title: Prevalence of Cognitive Impairment and Its Association With Activities of Daily Living Among Older Adults With Hematologic Malignancies Receiving Chemotherapy
This cross-sectional study aims to determine the prevalence of cognitive impairment and evaluate its relationship with activities of daily living among older adults with hematologic malignancies receiving chemotherapy.
Read the detailed description
Cognitive impairment is common among older adults with cancer and may affect treatment adherence and independence. This observational study will include adults aged 65 years or older with confirmed hematologic malignancies who are currently receiving chemotherapy.
Participants will undergo cognitive assessment using the Montreal Cognitive Assessment (MoCA) and functional assessment using the Katz Index of Activities of Daily Living (ADL) and Lawton Instrumental Activities of Daily Living (IADL).
- Keywords
- Cognitive impairment, Hematologic malignancies, Assiut, MoCA, Activities of daily living, Older adults
- Medical subject headings
- Cognitive Dysfunction, Hematologic Neoplasms
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
| Study group | Role | What they receive |
|---|---|---|
| Single cohort: Older adults with hematologic malignancies | Adults aged 65 years or older with hematologic malignancies receiving chemotherapy who will undergo cognitive and functional assessment. |
What is being measured
The primary outcome is the main question the study is designed to answer.
Prevalence of cognitive impairment
Proportion of participants with cognitive impairment defined as a Montreal Cognitive Assessment (MoCA) score less than 26.
Measured: Baseline
Secondary outcomes (5)
Mean MoCA score
Mean Montreal Cognitive Assessment (MoCA) score (range 0-30, higher scores indicate better cognition)..
Measured: Baseline
Mean Katz ADL score
Mean Katz Index of Independence in Activities of Daily Living score (range 0-6, higher scores indicate greater independence).
Measured: Baseline
Mean Lawton IADL score
Mean Lawton Instrumental Activities of Daily Living score (range 0-8, higher scores indicate greater independence)
Measured: Baseline
Proportion with impaired activities of daily living
Proportion of participants with impaired Katz ADL score.
Measured: Baseline
Proportion with impaired instrumental activities of daily living
Proportion of participants with impaired Lawton IADL score.
Measured: Baseline
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted25 Sep 2026
- Study start26 Sep 2026 (estimated)
- Primary completion26 Sep 2027 (estimated)
- Study completion25 Feb 2028 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Cognitive ImpairmentStudies of the same condition, open and under way.
- More trials run by Assiut UniversityThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Case only
- Time perspective
- Cross-sectional
- Enrolment
- 120 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Assiut University
- Sponsor type
- University, hospital or other
- Responsible party
- Principal investigator, Khloud Khaled Fawzy Kotby, Assiut University
- Investigators
- Soher M kasem, prof, Study chair, Internal Medicine Department, Assiut University Hospitals
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07842679
- Sponsor's protocol ID
- Cognitive-Hematology-Assiut-20
- Status last verified
- Sep 2026
- First submitted
- 21 Sep 2026
- Last updated
- 28 Sep 2026
- Results posted
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No
Study at a glance
From the registry record, last updated by the sponsor on 28 Sep 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Prevalence of Cognitive Impairment and Its Association With Activities of Daily Living Among Older Adults With Hematologic Malignancies Receiving Chemotherapy
- ClinicalTrials.gov ID
- NCT07842679
- Acronym / sponsor ID
- Cognitive-Hematology-Assiut-20
- Keywords
- Cognitive impairment, Hematologic malignancies, Assiut, MoCA, Activities of daily living, Older adults
- Study type
- Observational
- Recruitment status
- Not yet recruiting
- Enrolment
- 120 participants (estimated)
- Lead sponsor
- Assiut UniversityUniversity, hospital or other
- Study start
- 26 Sep 2026 (estimated)
- Primary completion
- 26 Sep 2027 (estimated)
- Study completion
- 25 Feb 2028 (estimated)
- First posted
- 25 Sep 2026 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
This cross-sectional study aims to determine the prevalence of cognitive impairment and evaluate its relationship with activities of daily living among older adults with hematologic malignancies receiving chemotherapy.
Detailed description
Cognitive impairment is common among older adults with cancer and may affect treatment adherence and independence. This observational study will include adults aged 65 years or older with confirmed hematologic malignancies who are currently receiving chemotherapy.
Participants will undergo cognitive assessment using the Montreal Cognitive Assessment (MoCA) and functional assessment using the Katz Index of Activities of Daily Living (ADL) and Lawton Instrumental Activities of Daily Living (IADL).
Study design
- Observational model
- Case only
- Time perspective
- Cross-sectional
- Number of arms
- 1
| Arm | Type | Receives |
|---|---|---|
| Single cohort: Older adults with hematologic malignancies | – | –Adults aged 65 years or older with hematologic malignancies receiving chemotherapy who will undergo cognitive and functional assessment. |
Who may qualify
- Ages
- 65 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Older adult
- Study population
- Older adults aged 65 years or older with confirmed hematologic malignancies receiving chemotherapy at Assiut University Hospitals.
Key inclusion criteria (5 listed)
- - Age 65 years or older
- Confirmed diagnosis of hematologic malignancy
- Currently receiving chemotherapy
- Able to communicate and participate in cognitive assessment
- Written informed consent
Key exclusion criteria (6 listed)
- - Previously diagnosed dementia before the diagnosis of malignancy
- Delirium at the time of assessment
- Severe visual or hearing impairment interfering with cognitive testing
- History of major neurological disorders affecting cognition
- Severe psychiatric illness affecting cognitive assessment
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Primary outcome
Prevalence of cognitive impairment
Time frame: Baseline
Proportion of participants with cognitive impairment defined as a Montreal Cognitive Assessment (MoCA) score less than 26.
5 secondary outcomes
Mean MoCA score
Time frame: Baseline
Mean Katz ADL score
Time frame: Baseline
Mean Lawton IADL score
Time frame: Baseline
Proportion with impaired activities of daily living
Time frame: Baseline
Proportion with impaired instrumental activities of daily living
Time frame: Baseline
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 28 Sep 2026.
- Individual participant dataSharing planned: No
Related trials for Cognitive Impairment
Enrolling by invitationPhase 4
Effects of Ciprofol on Perioperative Neurocognitive Function in Elderly Patients Undergoing Daytime Surgery
PND, POCD - Postoperative Cognitive Dysfunction
Recruiting
The Effects of Successful OSA Treatment on Memory and AD Biomarkers in Older Adults Study
Obstructive Sleep Apnea, Cognitive Decline
RecruitingObservational study
Development and Validation of Risk Prediction Models for Stroke and Cognitive Impairment in Moyamoya Disease and Moyamoya Syndrome
Moyamoya Disease, Moyamoya Syndrome
Recruiting
The Efficacy of an IADL-based Non-immersive Virtual Reality Training Program to Enhance ADL Performance and Cognitive Function for Persons at Risk of Dementia
Cognitive Enhancement, Subjective Cognitive Decline (SCD)
RecruitingPhase 2
Alzheimer's Tau Platform: Master Protocol
Preclinical Alzheimer's Disease, Alzheimer Disease
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
Soher M kasem, prof study chair
Internal Medicine Department, Assiut University Hospitals
Questions about this trial
What is this clinical trial studying?
An observational study of Cognitive Impairment and Hematologic Malignancies, run by Assiut University.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 5 inclusion and 6 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: opening soon, as of the sponsor's last update on 28 Sep 2026. Status can change between updates, so confirm with the study contact before making plans.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Contact Kholoud K Fawzy, Resident (01009850621, khloud.18313604@med.aun.edu.eg), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Prevalence of cognitive impairment (time frame: Baseline). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 28 Sep 2026.